found Documents: 389

Announcements & Press Releases, Oncology / Immunology, Press Releases | 26 Nov 2018

Chi-Med Announces First Commercial Launch of Fruquintinib Capsules (Elunate®)

1 item

London: Monday, November 26, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces the first commercial launch of fruquintinib capsules (Elunate®) with the initiation of product sales in China. Elunate® is for the

Chi-Med Announces First Commercial Launch of Fruquintinib Capsules (Elunate®)

Chi-Med Receives BayHelix R&D Achievement of the Year Award at BioCentury China Healthcare Summit

Chi-Med Announces Phase III FALUCA Trial Results for Fruquintinib in Third-Line, Advanced Non-Small Cell Lung Cancer in China

Chi-Med Initiates a Phase I Trial of HMPL-523 in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia in China

Chi-Med Announces the Approval of Fruquintinib Capsules for Previously Treated Colorectal Cancer in China

Chi-Med Reports 2018 Interim Results and Updates Shareholders on Key Clinical Programs

Chi-Med Initiates a Phase Ib/II Proof-of-Concept Trial of Sulfatinib in Pancreatic Neuroendocrine Tumors and Biliary Tract Cancer in the United States

Chi-Med to Announce 2018 Half-Year Financial Results

Chi-Med Presents Further Fruquintinib FRESCO Trial Data at ASCO 2018 Annual Meeting

Chi-Med to Present at Bank of America Merrill Lynch Annual Health Care Conference

2017 Annual Report and Notice of Annual General Meeting

Publication of Form 20-F for the Year Ended December 31, 2017

Chi-Med Reports Final Results for the Year Ended December 31, 2017 and Updates Shareholders on Key Clinical Programs

Chi-Med Initiates a Phase Ib/II Proof-of-Concept Trial of Epitinib in Glioblastoma in China

Chi-Med Completes Enrollment of 527 Patients in Pivotal Phase III FALUCA Trial with Fruquintinib in Lung Cancer

Chi-Med Initiates Fruquintinib U.S. Clinical Trials

Chi-Med Initiates FRUTIGA, a Phase III Trial of Fruquintinib in Second-Line Gastric Cancer

Chi-Med Announces the Closing of U.S. Public Offering of American Depositary Shares (ADSs) Raising Approximately US$301.3 Million on the Nasdaq Global Select Market

Chi-Med Announces the Full Exercise of Underwriters' Over-allotment Option

Chi-Med Announces Pricing of U.S. Public Offering of ADSs Raising US$262 Million on Nasdaq Global Select Market (RNS)

Chi-Med Announces Pricing of U.S. Public Offering of ADSs Raising US$262 Million on Nasdaq Global Select Market

Chi-Med Announces Proposed Offering of ADSs (RNS)

Chi-Med Announces Proposed Offering of ADSs

Chi-Med and AstraZeneca’s Savolitinib Shows Encouraging Clinical Activity in Second-Line EGFR Mutation-Positive Lung Cancer with MET-Amplification

Chi-Med Reports Preliminary Phase II data on Fruquintinib Combination in First-Line Lung Cancer

Chi-Med Appoints Professor Tony Mok to Board of Directors

Chi-Med Highlights Oral Presentations at CSCO Annual Meeting

Chi-Med to Present Savolitinib and Fruquintinib Clinical Data at WCLC 2017 Annual Meeting

Chi‑Med Initiates a Phase I Clinical Trial of Selective PI3Kδ Inhibitor HMPL‑689 in Lymphoma Patients in China

Chi-Med Reports 2017 Interim Results and Updates Shareholders on Key Clinical Programs

Chi-Med and AstraZeneca Initiate SAVOIR, a Global Phase III Trial of Savolitinib in Papillary Renal Cell Carcinoma

Chi-Med to Announce 2017 Half-Year Financial Results

Chi-Med Initiates a Phase I/II Clinical Trial of Novel FGFR Inhibitor HMPL-453 in China

Chi-Med Submits New Drug Application to CFDA for Fruquintinib in Advanced Colorectal Cancer

Chi-Med Highlights Phase III Fruquintinib Data in Oral Presentation at ASCO

Chi-Med Presents Clinical Data at ASCO 2017 Annual Meeting

Chi-Med Presented Pre-clinical Data for Fruquintinib and Sulfatinib at the American Association for Cancer Research Annual Meeting 2017

2016 Annual Report and Notice of Annual General Meeting

Chi-Med Appoints Weiguo Su, Chief Scientific Officer, to Board of Directors

Chi-Med to host R&D Briefings on March 29 & 30, 2017

Grant of Awards under Long Term Incentive Plan

Publication of Form 20-F for the Year Ended December 31, 2016

Chi-Med Reports Final Results for the Year Ended December 31, 2016 and Updates on Key Clinical Programs

Chi-Med Presented Sulfatinib Neuroendocrine Tumors Phase Ib/II Results at the 14th Annual Conference of the European Neuroendocrine Tumor Society

Chi-Med Announces Positive Top-Line Results for FRESCO, its Phase III Pivotal Registration Trial of Fruquintinib in Patients with Locally Advanced or Metastatic Colorectal Cancer

Chi-Med Appoints Graeme Jack as Independent Non-executive Director and Chairman of Audit Committee

Chi-Med Initiates a Phase II Study of Savolitinib in Pulmonary Sarcomatoid Carcinoma

Chi-Med Initiates First-In-Human Clinical Trial of Novel FGFR Inhibitor HMPL-453 in Australia

Chi-Med and AstraZeneca Present Savolitinib Papillary Renal Cell Carcinoma Phase II Results at 2017 Genitourinary Cancers Symposium

Chi-Med Appoints Industry Veteran Karen Ferrante to Board of Directors